

DAFTAR PUSTAKA

- Adepoju, P. (2020) 'Tuberculosis and HIV responses threatened by COVID-19', *The lancet. HIV*, 7(5), pp. e319–e320. doi: 10.1016/S2352-3018(20)30109-0.
- Ahmed, A. A, Grammatico, Megan, Moll, Anthony P., Malinga, Siphon., Makhunga, Philile, Charalambous, Salome, Ladines-Lim, Joseph B., Justin Jones, Koeun Choi & Sheela V. Shenoi (2021) 'Factors associated with low tuberculosis preventive therapy prescription rates among health care workers in rural South Africa', *Global Health Action*, 14(1). doi: 10.1080/16549716.2021.1979281.
- Alsdurf, H, Hill, P, Matteelli, A, Getahun, H & Menzies, D (2016) 'The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis', *The Lancet Infectious Diseases*, 16(11), pp. 1269–1278. doi: 10.1016/S1473-3099(16)30216-X.
- Apriani, L, Koesoemadinata, R, Bastos, M, Wulandari, D, Santoso, P, Alisjahbana, B, Rutherford, M, Hill, P, Benedetti, A, Menzies, D & Ruslami R (2022) 'Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia', *International Journal of Tuberculosis and Lung Disease*, 26(2), pp. 103–110. doi: 10.5588/ijtld.21.0318.
- Bastos, M, Melnychuk, L, Campbell, J, Oxlade, I, O & Menzies, D (2021) 'The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis', *PLoS Medicine*, 18(9), pp. 1–22. doi: 10.1371/journal.pmed.1003703.
- Bateman, C. (2011) 'Doctor IPT ignorance contributing to TB epidemic - Study', *South African Medical Journal*, 101(2), pp. 88–90. doi: 10.7196/samj.4734.
- Batista, L, Silva, K, Silva, L, Moura, Y & Zucchi, F (2020) 'Tuberculosis: A granulomatous disease mediated by epigenetic factors', *Tuberculosis*, 123(January). doi: 10.1016/j.tube.2020.101943.
- Berg, R. C., Page, S. and Øgård-Repål, A. (2021) 'The effectiveness of peer-support for people living with HIV: A systematic review and meta analysis', *PLoS ONE*, 16(6 June 2021), pp. 1–24. doi: 10.1371/journal.pone.0252623.
- Binarti, I. and Fitriyana, F. D. (2022) 'Analysis of Incomplete Medical Record Filling in Indonesia', *International Journal of Science and Society*, 4(1), pp. 347–357. doi: 10.54783/ijssoc.v4i1.441.
- Braa, J. Sundeep Sahay, John Lewis, and Wilfred Senyoni (2017) 'Health Information Systems in Indonesia: Understanding and Addressing Complexity', *IFIP Advances in Information and Communication Technology*, 504, pp. V–VI. doi: 10.1007/978-3-319-59111-7.
- Centers for Disease Control and Prevention (2022) *About HIV*, <https://www.cdc.gov/hiv/basics/whatishiv.html>.
- Charles, M, Lindegren, M, Wester, C, Blevins, M, Sterling, T, Dung, N, Dusingize, J, Avit-Edi, D, Durier, N, Castelnuovo, B, Nakigozi, G, Cortes, C, Ballif, M & Fenner, L (2016) 'Implementation of tuberculosis intensive case

- finding, isoniazid preventive therapy, and infection control (“Three I’s”) and HIV-tuberculosis service integration in lower income countries’, *PLoS ONE*, 11(4), pp. 1–12. doi: 10.1371/journal.pone.0153243.
- Codecasa, L, Murgia, N, Ferrarese, M, Delmastro, M, Repossi, A, Casali, L, Besozzi, G, Ferrara, G & Raviglione, M (2013) ‘Isoniazid preventive treatment: Predictors of adverse events and treatment completion’, *International Journal of Tuberculosis and Lung Disease*, 17(7), pp. 903–908. doi: 10.5588/ijtld.12.0677.
- Cowan, James., Cowan, G. Jessica., Barnhart, S. . et al (2017) ‘A Qualitative Assessment of Challenges to Tuberculosis Management and Prevention in Northern Ethiopia James’, *Journal of The International Society for Burn Injuries*, 43(5), pp. 909–932. doi: 10.5588/ijtld.12.0240.A.
- Deeks, S, Kitchen, C, Guo, L, Gascon, R, Narva’ez, A, Hunt, P, Martin, J, Kahn, J, Levy, J, McGrath, M & Hecht, F (2004) ‘Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load’, *Blood*, 104(4), pp. 942–947. doi: 10.1182/blood-2003-09-3333.
- Diedrich, C. R. and Flynn, J. A. L. (2011) ‘HIV-1/Mycobacterium tuberculosis coinfection immunology: How does HIV-1 exacerbate tuberculosis?’, *Infection and Immunity*, 79(4), pp. 1407–1417. doi: 10.1128/IAI.01126-10.
- Diel, R, Loddenkemper, R, Zellweger, J, Sotgiu, G, D’Ambrosio, L, Centis, R, Werf, M, Dara, M, Detjen, A, Gondrie, P, Reichman, L, Blasi, F & Migliori, G (2012) ‘Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination’, *Perspective Innovation in TB Control*, pp. 785–801. doi: 10.1183/09031936.00205512.
- Dinas Kesehatan Kota Yogyakarta (2023) *Profil Kesehatan Yogyakarta Tahun 2023*. Available at: <https://medium.com/@arifwicaksanaa/pengertian-use-case-a7e576e1b6bf>.
- Dinas Kesehatan Propinsi Daerah Istimewa Yogyakarta (2017) *Dinas Kesehatan Provinsi DIY*.
- Dinkes Sleman (2022) *Laporan Pelaksanaan Tugas Tahunan 2022*. Available at: www.dinkes.slemankab.go.id.
- Getahun, H., Gunneberg, C., et al. (2010) ‘HIV infection-associated tuberculosis: The epidemiology and the response’, *Clinical Infectious Diseases*, 50(SUPPL. 3), pp. 201–207. doi: 10.1086/651492.
- Getahun, H, Gunneberg, C, Granich, R & Nunn, P (2010) ‘Implementation of isoniazid preventive therapy for people living with HIV worldwide: Barriers and solutions’, *Aids*, 24(SUPPL. 5). doi: 10.1097/01.aids.0000391023.03037.1f.
- Ghimire, A, Mahendradhata, Y, Paudel, S, Yonzon, C, Bhuvan, Sharma, S & Utarini, A (2022) ‘Implementation fidelity of tuberculosis preventive therapy for under five children exposed to sputum smear positive pulmonary tuberculosis in Kaski district, Nepal: An implementation research’, *PLoS ONE*, 17(2 February), pp. 1–14. doi: 10.1371/journal.pone.0263967.

- Ginderdeuren Van, E. Bassett, Jean, Hanrahan, Colleen, Mutunga, Lillian, Van Rie, Annelies (2019) 'Health system barriers to implementation of TB preventive strategies in South African primary care facilities', *PLoS ONE*, 14(2), pp. 1–12. doi: 10.1371/journal.pone.0212035.
- Gupta, R, Lucas, S, Fielding, K & Lawn, S (2015) 'Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: A systematic review and meta-analysis', *Aids*, 29(15), pp. 1987–2002. doi: 10.1097/QAD.0000000000000802.
- Gust, D, Mosimaneotsile, B, Mathebula, U, Chingapane, B, Gaul, Z, Pals, S & Samandari, T (2011) 'Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana', *PLoS ONE*, 6(4). doi: 10.1371/journal.pone.0018435.
- Igbokwe, C. C., Abugu, L. I. and Aji, J. O. (2020) 'Assessment of tuberculosis intensified case finding and isoniazid preventive therapy for people living with hiv in enugu state, nigeria', *African Journal of Biomedical Research*, 23(3), pp. 367–373.
- Jacobson, K, Niccolai, L, Mtungwa, N, Moll, A & Shenoi, S (2017) "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa', *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV*, 29(7), pp. 936–942. doi: 10.1080/09540121.2017.1283390.
- Januraga, P. P., Reekie Joanne, Tri Mulyani, Bony Wiem Lestari, Shelly Iskandar, Rudi Wisaksana, Kusmayanti, Nur Aini, Subronto, Yanri Wijayanti, Desak Nyoman Widyantini, Dewa Nyoman Wirawan, Lydia Verina Wongso, Anindita Gabriella Sudewo, Evi Sukmaningrum, Tiara Nisa, Bagus Rahmat Prabowo, Matthew Law, David A Cooper, John M Kaldor (2018) 'The cascade of HIV care among key populations in Indonesia: a prospective cohort study', *The Lancet HIV*, 5(10), pp. e560–e568. doi: 10.1016/S2352-3018(18)30148-6.
- Jenkins, D. *et al.* (1992) 'An Outbreak of Tuberculosis with Accelerated Progression Among Person Infected with the Human Immunodeficiency Virus', *New England Journal of Medicine*, 329(1), pp. 21–26. Available at: <http://content.nejm.org/cgi/content/abstract/329/14/977%5Cnhttp://www.nejm.org/doi/abs/10.1056/NEJM199309303291401>.
- Karumbi, J. and Garner, P. (2015) 'Directly observed therapy for treating tuberculosis', *Cochrane Database of Systematic Reviews*, 2015(5). doi: 10.1002/14651858.CD003343.pub4.
- Kemenkes RI (2021) *Rencana Aksi Nasional Kolaborasi TB-HIV 2020-2024*. Available at: <https://tbindonesia.or.id/wp-content/uploads/2022/09/RAN-Kolaborasi-TB-HIV-2020-2024.pdf>.
- Komba, F. F. and Frumence, G. (2021) 'Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending care and treatment centers, Songea municipality, Tanzania', *Pan African Medical Journal*, 38. doi: 10.11604/pamj.2021.38.197.26752.
- Kwan, C. and Ernst, J. D. (2011) 'HIV and tuberculosis: A deadly human

- syndemic', *Clinical Microbiology Reviews*, 24(2), pp. 351–376. doi: 10.1128/CMR.00042-10.
- Lawn, S, Pisell, T, Hirsch, C, Wu, M, Butera, S, & Toossi, Z (2001) 'Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection', *Journal of Infectious Diseases*, 184(9), pp. 1127–1133. doi: 10.1086/323649.
- Lestari, T, Fuady, A, Yani, F, Artawan, W, Putra, E, Pradipta, I, Chaidir, L, Handayani, D, Fitriangga, A, Loprang, M, Pambudi, I, Ruslami, R & Probandari, A (2023) 'The development of the national tuberculosis research priority in Indonesia: A comprehensive mixed-method approach', *PloS one*, 18(2), p. e0281591. doi: 10.1371/journal.pone.0281591.
- Lester, R, Hamilton, R, Charalambous, S, Dwadwa, T, Chandler, C, Churchyard, G & Grant, A. (2010) 'Barriers to implementation of isoniazid preventive therapy in HIV clinics: A qualitative study', *Aids*, 24(SUPPL. 5), pp. 45–48. doi: 10.1097/01.aids.0000391021.18284.12.
- Lin, K.Y, Yang, C.J, Sun, H.J, Lee, Y.T, Liou, B.H, Hii, I.M, Chen, T.C, Huang, S.H, Lee, C.Y, Tsai, C.S, Lin, C.Y, Liu, C.E, Chang, H.Y, Cheng, C.Y, Lu, P.L & Hung, C.C (2022) 'Care cascade of tuberculosis infection treatment for people living with HIV in the era of antiretroviral therapy scale-up', *Scientific Reports*, 12(1), pp. 1–9. doi: 10.1038/s41598-022-20394-2.
- Maharaj Bhavna, Gengiah N. Tanuja, Yende-Zuma Nonhlanhla, et al (2019) 'Implementing Isoniazid Preventive Therapy in a TB-treatment experienced cohort on ART', *Physiology & behavior*, 176(3), pp. 139–148. doi: 10.5588/ijtld.16.0775.Implementing.
- Maison, D. P. (2022) 'Tuberculosis pathophysiology and anti-VEGF intervention', *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, 27(January), p. 100300. doi: 10.1016/j.jctube.2022.100300.
- Makanjuola, T., Taddese, H. B. and Booth, A. (2014) 'Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: A systematic review of qualitative data', *PLoS ONE*, 9(2). doi: 10.1371/journal.pone.0087166.
- Martinson, A, Barnes, G, Moulton, L, Msandiwa, R, Hausler, H, Ram, M, McIntyre, J, Gray, G & Chaisson, R (2011) 'New Regimens to Prevent Tuberculosis in Adults with HIV Infection', *New England Journal of Medicine*, 365, pp. 687–696.
- Mellors, J, Munoz, A & Giorgi, J (1997) 'Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.', *Annals of internal medicine*, 126(12), pp. 946–954. doi: 10.7326/0003-4819-126-12-199706150-00003.
- Méndez-Samperio, P. (2017) 'Diagnosis of Tuberculosis in HIV Co-infected Individuals: Current Status, Challenges and Opportunities for the Future', *Scandinavian Journal of Immunology*, 86(2), pp. 76–82. doi: 10.1111/sji.12567.
- Mindachew, M, Deribew, A, Memiah, P & Biadgilign, S (2014) 'Perceived barriers to the implementation of isoniazid preventive therapy for people living

- with HIV in resource constrained settings: A qualitative study', *Pan African Medical Journal*, 17, pp. 1–6. doi: 10.11604/pamj.2014.17.26.2641.
- Naif, H. M. (2013) 'Pathogenesis of HIV infection', *Infectious Disease Reports*, 5(SUPPL.1), pp. 26–30. doi: 10.4081/idr.2013.s1.e6.
- Nakata, K, Rom, W, Honda, Y, Condos, R, Kanegasaki, S, Cao, Y & Welden, M (1997) 'Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung', *Pneumologie*, 51(11), pp. 1052–1053.
- Namuwengea, P. M, Mukonzoc, J. K, Kiwanukaa, N, Wanyenzea, R, Byaruhangab, R, Bisselld, K & Zachariahe, R (2012) 'Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda', *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 106(2), pp. 84–89. doi: 10.1016/j.trstmh.2011.10.015.
- Narh-Bana, S. A. Mary Kawonga, Selase Adjoa Odopey, Frank Bonsu, Latifat Ibisomi and Tobias F. Chirwa (2022) 'Factors influencing the implementation of TB screening among PLHIV in selected HIV clinics in Ghana: a qualitative study', *BMC Health Services Research*, 22(1), pp. 1–12. doi: 10.1186/s12913-022-08295-6.
- Person, A. K. and Sterling, T. R. (2012) 'Treatment of latent tuberculosis infection in hiv: Shorter or longer?', *Current HIV/AIDS Reports*, 9(3), pp. 259–266. doi: 10.1007/s11904-012-0120-1.
- Russom, M. Daniel YB Jeannetot, Sirak Tesfamariam, Bruno H Stricker & Katia Verhamme (2022) 'Perspectives of Healthcare Professionals on Factors Limiting Implementation of Isoniazid Preventive Therapy in People Living with HIV in Eritrea: A Qualitative Study', *Risk Management and Healthcare Policy*, 15, pp. 1407–1419. doi: 10.2147/RMHP.S368315.
- Samandari, T, Agizew, T, Nyirenda, S, Tedla, Z, Sibanda, T, Shang, N, Mosimaneotsile, B, Motsamai, O, Bozeman, L, Davis, M, Talbot, E, Moeti, T, Moff, T, Kilmarx, P, Castro, K, Wells, C (2011) '6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: A randomised, double-blind, placebo-controlled trial', *The Lancet*, 377(9777), pp. 1588–1598. doi: 10.1016/S0140-6736(11)60204-3.
- Semitala, F, Musinguzi, A, Ssemata, J, Welishe, F, Nabunje, J, Kadota, J, Berger, C, Katamba, A, Kiwanuka, N, Kamya, M, Dowdy, D, Cattamanchi, A & Katahoire, A (2021) 'Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives', *Implementation Science Communications*, 2(1), pp. 1–12. doi: 10.1186/s43058-021-00173-2.
- Sonnenberg, P, Glynn, J, Fielding, K, Murray, J, Godfrey-Faussett, P & Shearer, S (2005) 'How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners', *Journal of Infectious Diseases*, 191(2), pp. 150–158. doi: 10.1086/426827.

- Sterling, T, Villarino, M, Borisov, A, Shang, N, Gordin, F, Bliven-Sizemore, E, Hackman, J, Hamilton, C, Menzies, D, Kerrigan, A, Weis, S, Weiner, M, Wing, D, Conde, M, Bozeman, L, Horsburgh, C & Chaisson, R (2011) 'Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection', *New England Journal of Medicine*, 365, pp. 687–696.
- Subbaraman, R, Nathavitharana, R, Satyanarayana, S, Pai, M, Thomas, B, Chadha, V, Rade, K, Swaminathan, S & Mayer, K (2016) 'The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis', *PLoS Medicine*, 13(10), pp. 1–38. doi: 10.1371/journal.pmed.1002149.
- Subbaraman, R, Nathavitharana, R, Mayer, K, Satyanarayana, S, Chadha, V, Arinaminpathy, N & Pai, M (2019) 'Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care', *PLoS Medicine*, 16(2), pp. 1–18. doi: 10.1371/journal.pmed.1002754.
- Surie, D, Interrante, J, Pathmanathan, I, Patel, M, Anyalechi, G, Cavanaugh, J & Kirking, H (2019) 'Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017', *International Journal of Tuberculosis and Lung Disease*, 23(12), pp. 1308–1313. doi: 10.5588/ijtld.19.0018.
- Suryanto, Plummer, V. and Boyle, M. (2017) 'Healthcare System in Indonesia', *Hospital topics*, 95(4), pp. 82–89. doi: 10.1080/00185868.2017.1333806.
- Tan, C, Idriss I. Kallon, Christopher J. Colvin, Alison D. Grant (2020) 'Barriers and facilitators of tuberculosis infection prevention and control in low-And middle-income countries from the perspective of healthcare workers: A systematic review', *PLoS ONE*, 15(10 October), pp. 1–18. doi: 10.1371/journal.pone.0241039.
- Teklay, G, Teklu, T, Legesse, B, Tedla, K & Klinkenberg, E (2016) 'Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: A mixed quantitative and qualitative study', *BMC Public Health*, 16(1), pp. 1–9. doi: 10.1186/s12889-016-3525-8.
- Tong, A., Sainsbury, P. and Craig, J. (2007) 'Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups', *International Journal for Quality in Health Care*, 19(6), pp. 349–357. doi: 10.1093/intqhc/mzm042.
- UNAIDS (2014) '90-90-90 An ambitious treatment target to help end the AIDS epidemic', *United Nations*.
- Utarini A (2022) *Penelitian Kualitatif Dalam Pelayanan Kesehatan*.
- Wambiya, E, Atela, M, Eboreime, E & Ibisomi, L (2018) 'Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: A qualitative study', *BMJ Open*, 8(12), pp. 1–10. doi: 10.1136/bmjopen-2018-024286.
- Van de Water, B. J, Meyer, T. N, Wilson, M, Gaunt, Y & Roux, K (2021) 'TB prevention cascade at a district hospital in rural Eastern Cape, South Africa', *Public Health Action*. Available at: <http://dx.doi.org/10.5588/pha.16.0125%0ASetting>:

- WHO (2004) *Report of A 'Lesson Learnt' Workshop on the Six ProTEST Pilot Project in Malawi, South Africa and Zambia, World Health Organisation.*
- WHO (2012) 'WHO policy on collaborative TB / HIV activities Guidelines for national programmes and other stakeholders', *Creative Lynx*, 330, pp. 2–36. doi: 23586124.
- WHO (2015) *Guidelines on the management of latent tuberculosis infection.* Available at: <https://www.who.int/publications/i/item/9789241548908>.
- WHO (2018a) *HIV Strategic Information for Impact Cascade Data Use Manual To Identify for Programme Health Services Gaps in Hiv and Improvement, HIV Strategic Information for Impact.* Available at: <http://apps.who.int/iris/bitstream/handle/10665/273119/9789241514415-eng.pdf?ua=1>.
- WHO (2018b) *Latent tuberculosis infection; Updated and consolidated guidelines for programmatic management, World Health Organisation.* doi: 10.1201/b20755-12.
- WHO (2019) *Tuberculosis & HIV*, <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/treatment/tuberculosis-hiv>.
- WHO (2020a) *Consolidated Guidelines on Tuberculosis Treatment, World Health Organisation.*
- WHO (2020b) *GLOBAL TUBERCULOSIS REPORT 2020, World Health Organisation.* doi: 10.1016/S0140-6736(00)58733-9.
- WHO (2021) *Global Tuberculosis 2021.*
- WHO (2022) *Fact Sheets Tuberculosis*, <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>.
- Winardi, W, Nalapraya, W, Sarifuddin, S, Anwar, S, Yufika, A, Wibowo, A, Fadhil, I, Wahyuni, H, Arliny, Y, Yanifitri, D, Zulfikar, T & Harapan, H (2022) 'Knowledge and Attitudes of Indonesian General Practitioners Towards the Isoniazid Preventive Therapy Program in Indonesia', *Journal of Preventive Medicine and Public Health*, 55(5), pp. 428–435. doi: 10.3961/jpmph.22.248.
- World Health Organization (2020) *A situational analysis of Programmatic Management of TB Preventive Treatment.*
- Yehia, B, Schranz, A, Umscheid, C & Re, V (2014) 'The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis', *PLoS ONE*, 9(7), pp. 3–9. doi: 10.1371/journal.pone.0101554.